Follow
Oncology Molecular Diagnostic
Clinical Oncology evaluations can include various molecular tests and the results can influence patient care. One example of an Oncology Molecular Diagnostic is mutation analysis for genes known to be confer a high risk of cancer such as BRCA1/2. Healthy patients found to carry this mutation benefit from increased screening and surveillance due to their increased risk of several cancers.
JUN 10, 2015 | 2:00 PM
Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...
MAR 10, 2015 | 9:00 AM
DATE: Tuesday, March 10, 2015 TIME: 09:00 PST, 11:00 CST, 12:00 EST, 16:00 GMTThe International Myeloma Working Group (IMWG) has issued updated criteria for the diagnosis of multiple...
FEB 10, 2015 | 12:00 PM
Date: Tuesday, February 10th, 2015Time: 12:00PM PST, 3:00PM ESTFor the last 60 years the primary method of preventing cervical cancer in both the U.S. and Europe has been cervical cytology ...
FEB 10, 2015 | 9:00 AM
Date: Tuesday, February 10th, 2015Time: 9:00AM PST, 12:00PM ESTFor the last 60 years the primary method of preventing cervical cancer in both the U.S. and Europe has been cervical cytology ...
FEB 04, 2015 | 12:00 PM
C.E. CREDITS
In Chile, the regulatory context regarding animal use in research is very poor. A legal framework for Animal Care and Use Committees is practically nonexistent. Also, the chilean culture play...
FEB 04, 2015 | 7:30 AM
C.E. CREDITS
During my presentation, we will discuss:- Normal patterns of behavior (repertoire): social, food intake, territorial, agonistic, anti-predation, sleep and rest, play behavior, grooming, sex...
FEB 04, 2015 | 6:00 AM
C.E. CREDITS
Soiled-bedding sentinels are not always efficient in detecting pathogens in rodent colonies. In this context, PCR-based testing can be more sensitive and is being advocated as adjunct to trad...
OCT 30, 2014 | 7:30 AM
Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved dr...
OCT 29, 2014 | 3:00 PM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
OCT 29, 2014 | 3:00 PM
Over the last decade we have witnessed tremendous advances in our understanding of the underlying molecular alterations in human cancer. This has stimulated excitement for our ability to deve...
OCT 29, 2014 | 9:00 AM
Although robust and clinically meaningful biomarkers are key to achieving the current vision for precision (molecularly based), cancer medicine (patient stratification, early diagnosis, drug...
OCT 29, 2014 | 7:30 AM
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. An...
SEP 24, 2014 | 11:00 AM
This presentation will focus on NuMediis general approach towards the discovery of new therapeutic uses for existing drugs. While the business models for repurposing marketed drugs versus rep...
SEP 10, 2014 | 10:00 AM
In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low...
MAY 30, 2014 | 7:30 AM
The value of measuring lactate levels is expanding. Though generally considered a nonspecific biomarker, knowing lactate levels early in a patients presentation can provide valuable informat...
MAY 29, 2014 | 7:30 AM
One of the major challenges to oncology based drug discovery and development has been the limited or incremental impact that many targeted agents have exhibited in the clinic. Understanding a...
